Katherine Young

6.5k citations

117 papers · 3.7k indexed · 1 hit paper · h-index 35

Impact in

Molecular Medicine top 0.1%
- Antibiotic Resistance in Bacteria
Applied Microbiology and Biotechnology top 0.1%
- Antibiotic Use and Resistance

Papers in

Applied Microbiology and Biotechnology 56
- Antibiotic Use and Resistance 56
Molecular Medicine 83
- Antibiotic Resistance in Bacteria 83

Co-authors: Mary Motyl Daniel F. Sahm Lynn L. Silver Sibylle Lob James A. Karlowsky Sheo B. Singh Krystyna M. Kazmierczak Ronald E. Painter
Journals: Open Forum Infectious Diseases (17 papers)Antimicrobial Agents and Chemotherapy (10 papers)Bioorganic & Medicinal Chemistry Letters (5 papers)International Journal of Antimicrobial Agents (5 papers)Clinical Infectious Diseases (4 papers)
Partner nations: United States Canada New Zealand

In The Last Decade

Katherine Young

113 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections 2019 · 284 citations

Peers

Countries citing papers authored by Katherine Young

Since Specialization

Citations

This map shows the geographic impact of Katherine Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine Young more than expected).

Fields of papers citing papers by Katherine Young

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine Young. The network helps show where Katherine Young may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Katherine Young, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Katherine Young Line = papers co-authored together Katherine Young links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Antimicrobial Activity of Imipenem/Relebactam and Comparator Agents Against Gram-Negative Isolates Collected From Pediatric Patients: SMART 2018–2022 Global Surveillance Journal of the Pediatric Infectious Diseases Society ·C Andrew DeRyke, Mark G. Wise, Karri A. Bauer, 王延博, Katherine Young, Mary Motyl, Daniel F. Sahm	2025	0
2	Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments of Olopatadine Hydrochloride/Mometasone Furoate Monohydrate and Azelastine Hydrochloride/Fluticasone Propionate for Allergic Rhinitis in Australia – An Observational Real-World Clinical Study Patient Preference and Adherence ·Simon Fifer, Mercedes Ruiz-Morales, Hanmant Barkate, 曲金鹏, Hege Raastad Basmo, Abonyi Oe, Godspower Anthony EKPULU, Merry C. Tabe, Katherine Young	2023	4
3	In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020 International Journal of Antimicrobial Agents ·James A. Karlowsky, Sibylle Lob, Wei‐Ting Chen, C Andrew DeRyke, 王延博, Katherine Young, Mary Motyl, Daniel F. Sahm	2023	3
4	Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates—SMART United States 2019–21 JAC-Antimicrobial Resistance ·James A. Karlowsky, Sibylle Lob, Karri A. Bauer, John S. Esterly, 王延博, Katherine Young, Mary Motyl, Daniel F. Sahm	2023	11
5	The Effectiveness of Imipenem–Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 β-Lactamase Antibiotics ·Krisztina M. Papp‐Wallace, Melissa D. Barnes, Magdalena A. Taracila, Christopher R. Bethel, Joseph Rutter, Natalia Kozioł, Katherine Young, Robert A. Bonomo	2023	6
6	Susceptibility of Gram-negative isolates collected in South Korea to imipenem/relebactam and comparator agents—SMART 2018–21 JAC-Antimicrobial Resistance ·James A. Karlowsky, Mark G. Wise, Wei‐Ting Chen, 王延博, Katherine Young, Mary Motyl, Daniel F. Sahm	2023	3
7	Yield of Facility-based Targeted Universal Testing for Tuberculosis With Xpert and Mycobacterial Culture in High-Risk Groups Attending Primary Care Facilities in South Africa Clinical Infectious Diseases ·Rebecca Berhanu, Limakatso Lebina, Bareng A. S. Nonyane, Minja Milovanovic, Anthony Kinghorn, Telmo Tavares Silva, Donglin Wang, Katherine Young, Harry Hausler, Pren Naidoo, Zameer Brey, Kate Shearer, 彰仁毛利, Neil Martinson	2023	13
8	Imipenem/Relebactam Resistance in Clinical Isolates of Extensively Drug Resistant Pseudomonas aeruginosa: Inhibitor-Resistant β-Lactamases and Their Increasing Importance Antimicrobial Agents and Chemotherapy ·Andrea M. Hujer, Christopher R. Bethel, Magdalena A. Taracila, Steven H. Marshall, Laura J. Rojas, Marisa Winkler, Ronald E. Painter, Tatiana Domitrovic, Richard Watkins, Ayman M. Abdelhamed, Roshan D’Souza, Andrew R Mack, Richard C. White, Thomas H. Clarke, Derrick E. Fouts, Michael R. Jacobs, Katherine Young, Robert A. Bonomo	2022	14
9	Evaluation of in vitro activity of ceftolozane/tazobactam and comparators against recent clinical bacterial isolates, and genomics of Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli isolates that demonstrated resistance to ceftolozane/tazobactam: data from Kuwait and Oman JAC-Antimicrobial Resistance ·Wadha Alfouzan, Lui Jiang-shen, R. Molenda, R. W. King, Eiman Mokaddas, Y. Nedelec, Abu Salim Mustafa, José L. Durán Gómez, Mika Aurela, G. Hammer, Zhong-Chi Wu, В.Н. Шигорина, Katherine Young	2022	4
10	In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018–20 JAC-Antimicrobial Resistance ·James A. Karlowsky, Sibylle Lob, Lillie Albrt, C Andrew DeRyke, 王延博, Katherine Young, Mary Motyl, Stephen Hawser, Daniel F. Sahm	2022	4
11	A DEEP LEARNING MODEL FOR INFERRING ELEVATED PULMONARY CAPILLARY WEDGE PRESSURES FROM THE 12-LEAD ELECTROCARDIOGRAM Journal of the American College of Cardiology ·Nathan H. LEDBETTER, Nathaniel Diamant, Aniruddh Raghu, Erik Reinertsen, Katherine Young, Puneet Batra, Eugene Pomerantsev, Collin M. Stultz	2022	2
12	In vitro activity of ceftolozane/tazobactam against Gram‐negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries—SMART 2017–2019 Journal of Global Antimicrobial Resistance ·Sibylle Lob, Krystyna M. Kazmierczak, Wei‐Ting Chen, 王延博, C Andrew DeRyke, Katherine Young, Mary Motyl, Daniel F. Sahm	2021	7
13	Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019 BMC Microbiology ·James A. Karlowsky, Sibylle Lob, Katherine Young, Mary Motyl, Daniel F. Sahm	2021	22
14	In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples – SMART Surveillance Europe 2015–2017 Journal of Medical Microbiology ·Sibylle Lob, James A. Karlowsky, Katherine Young, Mary Motyl, Stephen Hawser, Brian Fisher, Daniel F. Sahm	2020	50
15	Affinity Selection–Mass Spectrometry Identifies a Novel Antibacterial RNA Polymerase Inhibitor ACS Chemical Biology ·Scott S. Walker, David Degen, Elliott Nickbarg, Donna Carr, Aileen Soriano, عبدالوهاب شباب الشميلان, Ronald E. Painter, Payal R. Sheth, Li Xiao, Xinwei Sher, Nicholas Murgolo, Jing Su, David B. Olsen, Richard H. Ebright, Katherine Young	2017	14
16	Thiazomycin, nocathiacin and analogs show strong activity against clinical strains of drug-resistant Mycobacterium tuberculosis The Journal of Antibiotics ·Sheo B. Singh, Libo Xu, Peter T. Meinke, Natalia Kurepina, Barry N. Kreiswirth, David B. Olsen, Katherine Young	2017	8
17	Effect of Silver Nanoparticles and Antibiotics on Antibiotic Resistance Genes in Anaerobic Digestion Water Environment Research ·Jennifer Miller, John T. Novak, William R. Knocke, Katherine Young, Dorothy Bowhay, Peter J. Vikesland, Matthew S. Hull, Amy Pruden	2013	71
18	Side chain SAR of bicyclic β-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem Bioorganic & Medicinal Chemistry Letters ·Timothy A. Blizzard, Helen Chen, Seongkon Kim, Jane Y. Wu, Katherine Young, Young-Whan Park, Lewis Riley Taylor, Susan L. Raghoobar, Ronald E. Painter, Dimitris I. Tsioutsias, Sang Ho Lee, Andrew S. Misura, Antônio Augusto Braighi, Paula M.D. Fitzgerald, Nandini Sharma, Jun Lü, Sookhee Ha, Emily Hickey, N Jezequel, Milton L. Hammond	2009	22
19	Chemical Genetic Identification of Peptidoglycan Inhibitors Potentiating Carbapenem Activity against Methicillin-Resistant Staphylococcus aureus Chemistry & Biology ·Joann Huber, Robert G. K. Donald, Sang Ho Lee, Paolo Razuri C, Michael J. Salvatore, Xin Meng, Ronald E. Painter, Russell Onishi, James Occi, Karen Dorso, Katherine Young, Young Hwan Park, Stephen Skwish, Michael J. Szymonifka, David J. Haight, Lynn Miesel, John W. Phillips, Terry Roemer	2009	75
20	Inhibition of IMP-1 metallo-Î²-lactamase and sensitization of IMP-1-producing bacteria by thioester derivatives FEMS Microbiology Letters ·Gail G. Hammond, Joann Huber, Mark L. Greenlee, M. Stevenson, Katherine Young, Lynn L. Silver, James M. Balkovec, KellyAnn D. Pryor, Joseph K. Wu, Barbara Leiting, David L. Pompliano, Jeffrey H. Toney	1999	42

About Katherine Young

Katherine Young is a scholar working on Applied Microbiology and Biotechnology, Molecular Medicine, Pharmacology, Critical Care and Intensive Care Medicine and Epidemiology, having authored 117 papers that have together received 3.7k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (83 papers), Antibiotics Pharmacokinetics and Efficacy (62 papers), Antibiotic Use and Resistance (56 papers), Pneumonia and Respiratory Infections (22 papers), Microbial Natural Products and Biosynthesis (8 papers), Tuberculosis Research and Epidemiology (8 papers), Pharmaceutical and Antibiotic Environmental Impacts (8 papers) and Antimicrobial Resistance in Staphylococcus (6 papers). The work is most often cited by research in Molecular Medicine (2.2k citations), Applied Microbiology and Biotechnology (869 citations), Pharmacology (1.7k citations), Endocrinology (410 citations) and Clinical Biochemistry (301 citations). Katherine Young has collaborated with scholars based in United States, Canada and New Zealand. Frequent co-authors include Mary Motyl, Daniel F. Sahm, Lynn L. Silver, Sibylle Lob, James A. Karlowsky, Sheo B. Singh, Krystyna M. Kazmierczak, Ronald E. Painter, Sarah Hook and Thomas Rades. Their work appears in journals such as Open Forum Infectious Diseases, Antimicrobial Agents and Chemotherapy, Bioorganic & Medicinal Chemistry Letters, International Journal of Antimicrobial Agents and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact